Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935840 | 0.85 | KMT2A (0.52) | ANO1POLBRAB9AMEN1KMT2A | |
| SCHEMBL4929083 | 0.84 | PTPRC (0.49) | PTPRCHSD17B13RAB9AMEN1KMT2A | |
| SCHEMBL4930917 | 0.80 | ALDH1A1 (0.46) | POLBKDM4E | |
| SCHEMBL4925490 | 0.79 | CNR1 (0.45) | — | |
| SCHEMBL4931447 | 0.79 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4933912 | 0.79 | MEN1 (0.49) | PTPRCHSD17B13NPC1RAB9AMEN1 | |
| SCHEMBL24441381 | 0.78 | HSD17B13 (0.58) | HSD17B13 | |
| SCHEMBL4931432 | 0.78 | PTPRC (0.46) | PTPRCHSD17B13NPC1RAB9AMEN1 | |
| SCHEMBL4925482 | 0.77 | CDK2 (0.45) | — | |
| Hydrochloric Acid SCHEMBL4934603 | 0.76 | CDK2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | claimed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | claimed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| US-20080167309-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS, LTD. (UK) | 2008-07-10 | — | — | US | disclosed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167309-A1 | Pharmaceutical Compounds | CCNO, CDK2, CDK1 | ANO1 4621/4885PTPRC 1357/4885HSD17B13 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.